When it comes to therapeutics, I mentioned there's the C-TAP to develop the technology. The MPP is a patent pool from Unitaid, but it is a voluntary patent pool.
Both Merck and Pfizer have been using this—for example, Pfizer with Paxlovid—but at the same time, they can impose the conditions. Basically they said they would exchange the technology and make the patent accessible, but only for low-income countries under specific conditions. When Dominican Republic said that it wanted to use the compulsory licence for the therapeutic Paxlovid, Pfizer simply refused, claiming that this was their human right to decide what they want to do. This is nonsense.